Lugano, Switzerland, 7 February 2019 - The European Society for Medical Oncology (ESMO), (1) the leading professional organisation for medical oncology, is pleased to announce the TAT (Targeted Anticancer Therapies) International Congress 2019, (2) the premier forum for discussion of early phase drug developent and translational research.
The Congress, to be held 25-27 February in Paris, France, will bring together around 400 attendees from all over the world and is addressed to basic scientists, physicians and translational researchers from academic settings, industry and regulatory agencies for the common aim of speeding up the development of new anti-cancer treatment for the benefit of cancer patients.
The TAT Congress programme, (3) designed by a faculty of international renown experts, (4) will provide a glimpse into the future of cancer care; major updates and innovation in the field of cancer treatment using exciting novel targeted agents and immunotherapy will be presented along with new points to consider, including the role of liquid biopsies as alternative to conventional tissue biopsies. The issue of combination in the use of immunotherapeutic medicines will be largely discussed as well as new immuno-oncology methodological approaches, the inclusion of children and adolescents in early phase trials and the dynamic change in the distribution of cancer types in those trials.
In addition to the usual congress sessions, dedicated workshops and "Meet the Expert" sessions are planned to allow interactivity among participants.
During the opening session, (5) Dr. Geoffrey Shapiro will be presented the TAT 2019 Honorary Award (6) for his leadership in developmental therapeutics, particularly in solid tumours. Dr. Shapiro will deliver a keynote lecture entitled "Development of Cyclin-Dependent Kinase Inhibitors: A brief history and future directions".
ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration to the TAT International Congress 2019 is free to bona fide journalists on presentation of a letter of assignment and a valid press card.
Media representatives are required to observe and abide by the ESMO Media Policy. (7)
To register as press, please fill out the media registration form. (8)
We look forward to welcoming you in Paris.
ESMO Press Office
Notes to Editors
Please make sure to use the official name of the meeting in your reports: TAT International Congress 2019
Official Congress Hashtag: #TAT19
1 European Society for Medical Oncology (ESMO): https:/
4 TAT 2019 Congress Officers: https:/
5 TAT 2019 Opening Session https:/
6 TAT 2019 Honorary Award: https:/
7 ESMO Media Policy: https:/
8 Media Registration Form: http://esmo.
About the International Congress on Targeted Anticancer Therapies (TAT)
The TAT Congress is a peculiar ESMO event focusing on early phase drug development and translational research.
The TAT Congress series has been at the forefront of revolutionary transformation in early drug development and has succeeded in broadening the conversation on phase I trials to include a wide circle of stakeholders.
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 20,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. ESMO is committed to offer the best care to people with cancer, through fostering integrated cancer care, supporting oncologists in their professional development, and advocating for sustainable cancer care worldwide. Visit http://www.